Payment overview · 2025
General Payments
$396.29
20 reported records · 12 companies
Healthcare provider profile · identity verified
Suzan E Zimmer, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT PIERCE, FL · NPI 1750351151
Verified facts
What the public records show
CMS Open Payments records show Suzan E Zimmer, DO received $396.29 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.72 | 22.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.51 | 12.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.14 | 11.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.59 | 9.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.43 | 8.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.75 | 6.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.79 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.10 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.36 | 5.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.82 | 4.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $17.42 | 4.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.66 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.29 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.51 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.51 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.14 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 142 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Tartrate | Metoprolol Tartrate | 340 | 70 |
| Gabapentin | Gabapentin | 319 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 68 |
| Losartan Potassium | Losartan Potassium | 254 | 65 |
| Omeprazole | Omeprazole | 250 | 65 |
| Lisinopril | Lisinopril | 244 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 64 |
| Metformin Hcl | Metformin Hcl | 231 | 60 |
| Potassium Chloride | Potassium Chloride | 175 | 52 |
| Sertraline Hcl | Sertraline Hcl | 163 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 40 |
| Alprazolam | Alprazolam | 154 | 31 |
| Eliquis | Apixaban | 142 | 31 |
| Tramadol Hcl | Tramadol Hcl | 139 | 31 |
| Meloxicam | Meloxicam | 138 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 40 |
| Furosemide | Furosemide | 123 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | 14 |
| Simvastatin | Simvastatin | 109 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 18 |
| Allopurinol | Allopurinol | 84 | 21 |
| Lorazepam | Lorazepam | 80 | 18 |
| Trazodone Hcl | Trazodone Hcl | 77 | 25 |
| Montelukast Sodium | Montelukast Sodium | 75 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 21 |
| Temazepam | Temazepam | 69 | 12 |
| Gemfibrozil | Gemfibrozil | 67 | 18 |
| Nifedipine Er | Nifedipine | 66 | 17 |
| Levetiracetam | Levetiracetam | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 14 |
| Lovastatin | Lovastatin | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Azithromycin | Azithromycin | 43 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 12 |
| Prednisone | Prednisone | 42 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 15 |
| Carvedilol | Carvedilol | 40 | 17 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 11 |
| Glipizide | Glipizide | 38 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 12 |
| Fentanyl | Fentanyl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Carisoprodol | Carisoprodol | 34 | suppressed |
| Lacosamide | Lacosamide | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Methocarbamol | Methocarbamol | 33 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Finasteride | Finasteride | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.29 · 20 records | AstraZeneca Pharmaceuticals LP | BREZTRI, CAPLYTA, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VYNDAQEL | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error